Media Highlights

Media Highlights

For the Media

Dr. Sekeres on the FDA Approval of Imetelstat in Lower-Risk MDS With Anemia

June 07, 2024

Dr. Mikkael A. Sekeres discusses the significance of the FDA approval of imetelstat (Rytelo) for patients with lower-risk myelodysplastic syndromes (MDS) and transfusion-dependent anemia.

Read the Full article

Tags:   Mikkael A. Sekeres, Sylvester Comprehensive Cancer Center